EGFR and non-small cell lung carcinoma: In a real-world study (45), 62 NSCLC patients with EGFR ex20ins mutations were orally administered osimertinib 80 mg/once-daily (QD), revealing that disease Control Rate(DCR) was 53.2% with an ORR of 6.5%.